Therapeutic effects of insulin detemir on poorly-controlled type 2 diabetes with oral antidiabetic drugs
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF DIABETES
- Issue:
- 5
- DOI:
- 10.3969/j.issn.1006-6187.2011.05.007
- Key Word:
- 糖尿病,2型;地特胰岛素;口服降糖药;Diabetes mellitus, type 2;Insulin detemir;Oral antidiabetic drugs
Abstract： Objective To investigate the efficacy and safety of insulin detemir in poorly controlled type 2 diabetes (T2DM) with oral antidiabetic drugs. Methods33 cases T2DM patients with inadequate glycemic control were given insulin detemir at bedtime daily on the basis of their oral agents for 24 weeks. FBG, 2h BG, HbA1c and BMI were compared before and after the treatment. ResultsFBG, 2h BG and HbA1c were significantly lower in post-treatment with insulin detemir than in pre-treatment (P＜0.01）. Incidence of mild hypoglycemia was 9.1%, and there was no symptomatic hypoglycemia. Conclusion Insulin detemir could efficiently inprove diabetes care in poorly controlled T2DM with oral antidiabetic drugs, with a lower incidence of hypoglycemia and no obvious increment of body weight.
- [1]Havelund S,Plum A,Ribel U,etc.The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.[J].2004,21(8).
- [2]Klein O,Endahl L,Nosek L,etc.Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.[J].2007,9(3).
- [3]Luddeke HJ,Sreenan S,Merilainen M,etc.Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data f[J].2008,10(1).
- [4]Martinez Ravn G,Clauson P,Home P,etc.A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.[J].2006,29(6).
- [5]Bodenlenz M,Draeger E,Magnes C,etc.A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.[J].2005,28(5).